Clinical Trial Update: CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies [Phase 1, Phase 2]

View source ↗

Summary

An update on an ongoing Phase 1/2 clinical trial evaluating CD5-targeted CAR T cells for relapsed or refractory T-cell malignancies, including T-cell acute lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• T-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• CD5 CAR-T cells (CD5-targeted chimeric antigen receptor T cells)

Snippet

Sponsor: Beijing GoBroad Hospital | Conditions: T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | Phase 1, Phase 2 | Status: RECRUITING